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Abstract
Aim: Development of robust prognostic and/or predictive biomarkers in patients with colorectal cancer (CRC) is imperative
for advancing treatment strategies for this disease. We aimed to determine whether expression status of certain miRNAs
might have prognostic/predictive value in CRC patients treated with conventional cytotoxic chemotherapies.
Methods: We studied a cohort of 273 CRC specimens from stage II/III patients treated with 5-fluorouracil-based adjuvant
chemotherapy and stage IV patients subjected to 5-fluorouracil and oxaliplatin-based chemotherapy. In a screening set
(n = 44), 13 of 21 candidate miRNAs were successfully quantified by multiplex quantitative RT-PCR. In the validation set
comprising of the entire patient cohort, miR-148a expression status was assessed by quantitative RT-PCR, and its promoter
methylation was quantified by bisulfite pyrosequencing. Lastly, we analyzed the associations between miR-148a expression
and patient survival.
Results: Among the candidate miRNAs studied, miR-148a expression was most significantly down-regulated in advanced
CRC tissues. In stage III and IV CRC, low miR-148a expression was associated with significantly shorter disease free-survival
(DFS), a worse therapeutic response, and poor overall survival (OS). Furthermore, miR-148a methylation status correlated
inversely with its expression, and was associated with worse survival in stage IV CRC. In multivariate analysis, miR-148a
expression was an independent prognostic/predictive biomarker for advanced CRC patients (DFS in stage III, low vs. high
expression, HR 2.11; OS in stage IV, HR 1.93).
Discussion: MiR-148a status has a prognostic/predictive value in advanced CRC patients treated with conventional
chemotherapy, which has important clinical implications in improving therapeutic strategies and personalized management
of this malignancy.
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Introduction
Currently, colorectal cancer (CRC) patients with lymph node
metastasis (TNM stage III) are treated with adjuvant chemother-
apy that includes cytotoxic drugs such as 5-fluorouracil (5-FU) and
oxaliplatin, following surgical resection of the cancer. Similarly,
patients with distant metastatic CRC (stage IV) are treated with
various combinations of chemotherapeutic drugs and molecularly-
targeted drugs that include anti-VEGF and anti-EGFR antibodies.
Although these treatment regimens have improved outcomes in
patients with advanced CRC, a significant proportion of
individuals fail to derive any benefit from such treatments, and
some experience worse outcomes as a result of drug-associated
toxicities. There is an imperative need for developing predictive
biomarkers that can select the subgroup of patients that will benefit
from conventional chemotherapeutic drugs, so that patients who
will not benefit from the treatment can be spared from drug
toxicity and offered alternate treatments.
Mutations in KRAS are the only established predictive markers
for selecting treatment strategies in CRC. Patients with tumors
harboring mutations in codon 12 or 13 of the KRAS gene do not
benefit from anti-EGFR-based drug therapy [1,2], and conse-
quently, screening for this mutation is recommended for all stage
IV patients who are candidates for anti-EGFR antibody-based
drug therapy. In addition, microsatellite instability (MSI), a
phenotype present in ,15% of CRCs, has been shown to
associate with improved overall survival (OS) regardless of
adjuvant chemotherapy, as well as a lack of benefit from 5-FU-
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based chemotherapy in stage II patients [3,4]. However, whether
MSI has predictive value in stage III patients treated with
chemotherapy remains uncertain [5,6]. While some studies have
suggested that other molecular markers, such as the CpG island
methylator phenotype or expression status of genes involved in
DNA repair or drug metabolism (such as ERCC1 and TYMS) may
have potential as prognostic/predictive markers, there is insuffi-
cient consistent data supporting the usefulness of these markers [7–
11]. Taken together, in spite of strides made in the genomic and
epigenomic characterization of CRC, there are no established
biomarkers that can reliably predict therapeutic outcomes from
conventional cytotoxic chemotherapy in patients with stage III or
IV CRC.
Dysregulation of microRNA (miRNA) expression is implicated
in early tumorigenesis as well as disease progression in various
malignancies [12,13]. miRNAs exert their oncogenic and/or
tumor suppressive effects by binding to the 39-untranslated regions
of mRNA, leading to suppression of translation or enhanced
degradation of the corresponding message. In CRC, dysregulated
expression of several miRNAs, including the miR-17,92, miR-21,
miR-31, miR-34b/c, miR-143, miR-145, and miR-203 have been
previously reported [14–17]. Since miRNAs play a central role in
human carcinogenesis, there is growing interest in the identifica-
tion of prognostic or predictive miRNAs in patients with CRC.
However, only a handful of reports have investigated the
potential of miRNA(s) as prognostic/predictive biomarkers in
CRC. In a seminal study, Schetter et al. demonstrated that miR-21
may be a promising prognostic/predictive marker in stage II/III
CRC treated with 5-FU-based chemotherapy [17]. Similarly,
another group has shown that stage II patients with elevated
expression of miR-320 or miR-498 had better recurrence-free
survivals [18]. However, the sample sizes analyzed in these studies
were relatively small, the results have not been validated in other
studies, and there has been no attempt to determine the predictive
utility of any miRNA in stage IV CRC. We hypothesized that the
expression profiles of specific miRNA(s) might have prognostic
and/or predictive value in patients with stage IV CRC as well as
those with earlier stages. Herein, in an initial screening step that
involved analysis of 21candidate miRNAs, we discovered that
miR-148a is frequently downregulated in advanced CRC.
Subsequently, by analyzing a large validation cohort of 273
CRCs, we provide novel evidence that miR-148a is frequently
down-regulated in this disease, and this principally occurs through
hypermethylation of its putative promoter region. In addition, we
demonstrate that low miR-148a expression is significantly
associated with an unfavorable outcome in patients with stage
III CRC treated with 5-FU-based chemotherapy and with a worse
therapeutic response and survival in patients with stage IV CRC
treated with 5-FU and oxaliplatin.
Patients and Methods
Ethics Statement
The study was approved by the Institutional Review Boards
(IRB) of Hospital Clinic, Barcelona, Spain, and a written informed
consent was obtained from all patients.
Patients
Formalin-fixed paraffin-embedded (FFPE) tissues from a cohort
of 273 patients with CRC (primary tumors from 76 stage II, 125
stage III, and 72 stage IV CRCs) and 20 tissue specimens from
normal colonic mucosa of healthy individuals were obtained from
the Pathology Department of the Hospital Clinic, Barcelona,
Spain. The patients included in this study were enrolled between
1996 and 2008. All stage II and III patients were treated with 5-
FU-based adjuvant chemotherapy for 6 months subsequent to
tumor resection, and all stage IV patients were treated with 5-FU
and oxaliplatin until the treatment failed. The stage II and III
patients were followed-up every three months for the first two
years, and every six months for the subsequent three years. Both
locoregional relapse and/or distant metastasis were defined as
tumor recurrence, whereas metachronous colorectal lesions were
not considered as recurrence. The median follow-up times are
52.2 months (range; 2.9–173 months) in stage II and III patients,
and 19.1 months (range; 3.7–83.7 months) in stage IV patients.
Among stage II and III patients, 70 patients (35%) had tumor
recurrence (median; 17.8 months, range: 5.5–144 months), and
the median DFS of non-recurrence patients were 40.5 months
(range; 7.5–155 months). The follow-up of patients was finished in
November, 2009. Chemotherapeutic response in stage IV patients
was evaluated according to the Response Evaluation Criteria In
Solid Tumors (RECIST) guidelines [19] every two months. MSI
status of tumors was determined by analyzing five mononucleotide
markers (BAT-25, BAT-26, MONO-27, NR-21, and NR-24; MSI
Analysis System, Promega, Madison, Wisconsin, USA). The
clinicopathological characteristics of the patients are shown in
Table 1.
DNA and RNA extraction
DNA was extracted from 10 mm-thick FFPE tissues using the
QIAmp DNA FFPE tissue kit (Qiagen, Valencia, California,
USA). Total RNA including the miRNA fraction was extracted
from FFPE tissues using the RecoverAll Total Nucleic Acid
Isolation Kit (Ambion, Inc., Austin, Texas, USA).
Multiplex quantitative RT-PCR
In a screening set that included normal colonic mucosa from
healthy subjects and 44 CRC tissues (16 stage II and III each and
12 stage IV patients), the expression status of 21 candidate
miRNAs (miR-9, miR-10b, miR-19a, miR-21, miR-31, miR-34a,
miR-34c, miR-101, miR-103, miR-137, miR-143, miR-145, miR-
148a, miR-148b, miR-152, miR-155, miR-194, miR-320, miR-
335, miR-373 and miR-519c) was quantified using the high-
throughput Fluidigm microfluidics dynamic arrays [20]. Each
Taqman miRNA assay (part no. 4427975, Applied Biosystems,
Foster City, California, USA) was used in the multiplex RT-PCR
analysis as follows: assay ID, 000583, 002218, 000395, 000397,
002279, 000426, 000428, 002253, 000439, 001129, 002249,
002278, 000470, 000471, 000475, 002623, 000493, 002277,
000546, 000561, and 001163, respectively. These candidate
miRNAs have previously been shown to be involved in CRC
and/or other human malignancies [16,18,21–35].
Quantification of miRNA expression by real-time RT-PCR
In the validation set that included the entire patient cohort,
miRNA expression was quantified by Taqman reverse transcrip-
tion-PCR (qRT-PCR) using an ABI 7000 sequence detection
system (Applied Biosystems). The expression of miR-148a was
calculated by the delta Ct value method, using miR-16 expression
as a normalizer [36,37]. To keep consistent measurements
throughout all plates, three independent RNA samples were
loaded as internal controls in each PCR run, and the results from
each plate were normalized according to data obtained from
internal controls.
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DNA methylation analysis
DNA was bisulfite modified using the EZ DNA methylation
Gold Kit (Zymo Research, Irvine, California, USA). Methylation
of putative miR-148a promoter region was quantified by bisulfite
pyrosequencing (PSQ HS 96A pyrosequencing system, Qiagen).
The following primers were used; miR-148a forward, 59-biotin-
TAGGAAGGAAGGAGAGTG, miR-148a reverse, 59-CCCAA-
CAAAAATAATATTTTAACA, and miR-148a sequencing, 59-
CAAAAATAATATTTTAACAACC. The methylation levels of
three CpG sites were analyzed and the methylation level of each
tumor is represented as the mean value of methylation levels of the
three CpG sites. The following PCR cycle conditions were used:
initial denaturation at 94uC for 7 min, followed by 45 cycles at
94uC for 30 sec, 52uC for 30 sec, and 72uC for 30 sec.
In situ hybridization for miR-148a
In situ hybridization (ISH) was performed as described by
Navarro et al. [38] with minor adjustments. A fluorescein (FITC)
59-labeled locked nucleic acid-incorporated miRNA probe (miR-
CURY LNA detection probe, Exiqon, Woburn, Massachusetts,
USA) was used for visualization of miR-148a on 3 mm-thick FFPE
tissue sections. A scrambled and an RNU6b probe were included
as negative and positive controls, respectively (Exiqon). The slides
were placed in an oven at 59uC overnight. Sections were
deparaffinized with xylene, rehydrated with ethanol, and treated
with diethylpyrocarbonate water for 1 min. Chromogenic ISH
was performed in an automated platform Bond Max (Vision
BioSystems, Norwell, Massachusetts, USA). Slides were pretreated
with protease 1 for 4 min at 37uC. A total of 300 ml 25-nM probe
was hybridized in sodium chloride, sodium citrate hybridization
buffer at 45uC overnight. Immunologic detection was performed
with a mouse anti-FITC antibody at 37uC for 60 min followed by
a biotin-free, polymeric horseradish peroxidase linker antibody
conjugate system (Refine Detection System, Vision BioSystems).
DAB was used as the chromogen and hematoxylin was used as a
counterstain.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 4.0
(GraphPad Software, La Jolla, California, USA) or MedCalc v12
(MedCalc software, Belgium). The differences between two groups
were analyzed by the Mann-Whitney U-test. Correlation analyses
were carried out using Spearman’s rank correlation method. The
CRC tumors were categorized into high and low miR-148
expression groups using Receiver Operating Characteristic curve
analysis (stage II/III) or the median expression values (stage IV).
Kaplan-Meier analysis was performed to estimate the distributions
of disease-free survival (DFS) and cancer-specific overall survival
(OS) in stage II and III patients, and progression-free survival
(PFS) and OS in stage IV patients. A log-rank test was used to
analyze the statistical differences in survival as deduced from
Kaplan-Meier curves. Cox proportional-hazard regression analysis
was performed to calculate HR and 95% CI for each covariable.
The final multivariate model was based upon a stepwise method
for clinical factors associated with good or poor survival (p,0.1) in
univariate models. For the survival analysis, the solitary MSI
tumor was excluded from the stage IV group. All differences were
regarded as statistically significant when p,0.05.
Results
miR-148a is a candidate miRNA which is frequently
down-regulated in stage III and IV CRC
In a screening set, we first screened 21 candidate miRNAs that
have been implicated in tumorigenesis, using the Fluidigm
microfluidics dynamic arrays (n = 44; Supplementary Table
Table 1. MiR-148 expression status and clinicopathologic characteristics of CRC patients.
Stage II+III Stage IV
High expression Low expression High expression Low Expression
(n = 138) (n = 63) (n = 36) (n = 36)
N % N % p N % N % p
Age, years Median 66.5 68.5 0.13a 58.5 62.0 0.36a
Range 32–82 45–82 43–78 36–79
Gender Male 79 57 39 62 0.64b 25 69 22 61 0.62b
Female 59 43 24 38 11 31 14 39
Tumors locationc Proximal 39 28 22 35 0.41d 10 28 5 14 0.35d
Distal 99 72 41 65 20 56 24 67
Rectum 0 0 0 0 6 17 7 19
MSI Yes 8 6 6 10 0.38b 0 0 1 3 1.00b
No 130 94 57 90 36 100 35 97
Performance status 0–1 32 89 31 86 1.00b
2 4 11 5 14
Tumor response CR+PR 29 81 17 47 0.006b
SD+PD 7 19 19 53
aThe difference was analyzed by Mann-Whitney U test.
bThe difference was analyzed by Fisher’s exact test.
cProximal colon, located above splenic flexure; distal colon, located in splenic flexure or below.
dThe difference was analyzed by the chi-square test.
doi:10.1371/journal.pone.0046684.t001
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S1). Among the 21 miRNAs analyzed, 13 miRNA successfully
yielded expression results in the multiplex RT-PCR. Seven
miRNAs demonstrated significantly altered expression between
normal and CRC tissues. Among all, only miR-148a revealed a
significant down-regulation in tumors with lymph node (stage III)
or distant metastasis (IV) compared to tumors without (II), which
underscores the significance of this miRNA in CRC progression/
metastasis. Based upon these results, we subsequently determined
Figure 1. MiR-148a expression and methylation in colonic mucosa from healthy individuals and in CRC tissues from patients. A. miR-
148a expression in colonic mucosa from healthy controls (NC), and in stage II, III and IV CRCs; the number of patients (N) and median expression
(Median) are listed below the graph. B. In situ hybridization for miR-148a in CRC tumors and normal mucosa, in which the chromogen stains red, and
the counterstain blue. Representative photomicrographs are shown from a normal colonic mucosa (top panels), a tumor with low miR-148a
expression (middle panels), and a tumor with high miR-148a expression (lower panels) at indicated magnifications. A photomicrograph is shown from
a tumor with high miR-148a expression using a scramble probe as a negative control (bottom, left panel). C. miR-148a methylation levels in stage IV
tumors. The putative promoter region of miR-148a, and the position of pyrosequencing primers are illustrated in the top panel. The scatter plot of
miR-148a expression and methylation levels are shown in the bottom panel. D. miR-148a expression levels are shown for methylated and non-
methylated CRCs in the top panel. miR-148a methylation levels are shown for tumors with high and low miR-148a expression in the bottom panel.
One outlier value (the methylation level; 48%) is excluded from the methylated group in the bottom graph.
doi:10.1371/journal.pone.0046684.g001
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whether a miR-148a expression alteration in a larger cohort of
CRC has any prognostic/predictive value.
In our entire cohort (n = 273), miR-148a expression in stage
III/IV tumors was significantly lower than in normal colonic
mucosa (p,0.001; Figure 1A). We also observed a trend toward
gradual lowering of miR-148a expression with advancing stage of
the CRCs (Figure 1A). More specifically, miR-148a expression in
stage III and IV tumors was significantly lower than in normal
colonic mucosa (p,0.001), while it was not significantly different
between stage II tumors and the normal mucosal specimens
(p = 0.41; Figure 1A).
Next, to confirm the tumor-specific expression pattern for miR-
148a, we performed ISH analysis in a subset of stage IV tumors
with high and low miR-148a expression. We observed that
expression in normal colonic mucosa of stage II tumors was high,
confirming the qRT-PCR results (Figure 1B). CRCs with high
miR-148a expression at qRT-PCR also expressed this miRNA
primarily within the cytoplasm of neoplastic cells (Figure 1B), but
not in the non-epithelial stromal cells, except for the staining of
some inflammatory cells in the lamina propria, particularly the
plasma cells. Furthermore, CRCs with low miR-148a expression
ascertained by qRT-PCR also revealed very low or absent
expression of this miRNA at the ISH level (Figure 1B). These
results indicate that our qRT-PCR results accurately reflected the
endogenous expression of miR-148a within the cancer cells
obtained from CRC tissue specimens.
Expression of miR-148a is inversely correlated with its
promoter methylation status
The putative promoter region of miR-148a sites within a CpG
island, and methylation of these CpG sites have been proposed as
a potential mechanism for miR-148a inactivation in CRC and
breast cancers [39–41]. However, none of previous studies have
thoroughly investigated the direct correlation between miR-148a
expression and its methylation status in a large cohort of cancer
specimens. Accordingly, we were interested in elucidating whether
the down-regulation of miR-148a observed in our cohort was a
consequence of promoter hypermethylation. Since miR-148a was
most frequently down-regulated in stage IV CRC, we focused our
methylation analysis on these tumors. Quantitative bisulfite
pyrosequencing revealed that some stage IV CRCs demonstrated
miR-148a hypermethylation. The methylation levels ranged
between 4–26% (median, 10%), and when the methylation status
of each tumor was compared with its qRT-PCR-derived
expression status, a significant correlation was observed (Spear-
man’s coefficient, R2 = 20.43, p,0.001; Figure 1C). Addition-
Figure 2. Survival analysis in stage II/III patients treated with 5-FU-based chemotherapy. Kaplan-Meyer curves for A, Disease-free survival
(DFS) and B, overall survival (OS) in stage II/III patients according to miR-148a expression. Kaplan-Meyer curves for C, DFS in stage II and D, stage III
DFS depending upon miR-148a expression.
doi:10.1371/journal.pone.0046684.g002
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ally, when we categorized all tumors into a non-methylated
(methylation level ,15%) and methylated groups ($15% meth-
ylation), we observed that the methylated tumors had consistently
lower miR-148a expression (0.068 vs. 0.088, p = 0.029;
Figure 1D, top). Furthermore, CRCs with lower miR-148a
expression were more frequently methylated compared to tumors
with higher expression (median, 11% vs. 8%, p = 0.001, Mann-
Whitney U test; Figure 1D, bottom). These results highlight
that the hypermethylation of the putative miR-148a promoter
region is an important regulatory mechanism for its expression in
CRC.
Low miR-148a expression is associated with poor
outcome in patients with stage II and III CRC
We next aimed to determine whether miR-148a expression
status had an impact on prognosis in patients with stage II and III
CRC treated with 5-FU-based adjuvant chemotherapy. For these
analyses, we compared the differences in DFS and OS between the
high expression (stage II = 58, III = 80) and low expression (II = 18,
III = 45) groups. We did not find significant associations between
the miR-148a expression and any of the clinicopathological factors
such as age, gender, tumor location or MSI status (Table 1).
However, low miR-148a expression was significantly associated
with shorter DFS (5-year DFS, low vs. high, 54% vs. 71%,
p = 0.023; Figure 2A), and showed a trend toward worse OS (5-
year OS, 78% vs. 85%, p = 0.12; Figure 2B). We next evaluated
the prognostic/predictive value of miR-148a expression in a Cox
proportional hazard regression model. In univariate analysis,
higher TNM stage (III vs. II, HR 2.06, 95% CI 1.21–3.52,
p = 0.008) and lower miR-148a expression (HR 1.74, 95% CI
1.08–2.83, p = 0.025) were significantly associated with shorter
DFS, and younger age showed a trend towards shorter DFS (,60,
HR 1.57, 95% CI 0.97–2.56, p = 0.071; Table 2). Furthermore,
in the multivariate model including these three factors, miR-148a
expression status was independently associated with worse survival
(HR 1.83, 95% CI 1.12–2.99, p = 0.017; Table 2).
We next analyzed data from stage II and III CRC separately to
determine whether the association between low miR-148a
expression and worse outcome was uniform across both stages,
or predominantly aligned with one stage. We found that in stage
II, miR-148a expression did not associate with DFS (5-year DFS,
high vs. low, 77% vs. 83%, p = 0.50; Figure 2C) or OS (5-year
OS, 89% vs. 87%, p = 0.94; data not shown). However, in stage
III, low miR-148a expression was significantly associated with
poorer DFS (5-year DFS, 43% vs. 66%, p = 0.0071; Figure 2D)
but not with OS (5-year OS, 75% vs. 81%, p = 0.16; data not
shown). Moreover, low miR-148a expression was an only factor
that associated with tumor recurrence in stage III (Table 2).
These results suggest that miR-148a expression status has a
potential as a prognostic/predictive biomarker for stage III CRC.
Low miR-148a expression is associated with worse a
therapeutic response and worse survival in stage IV CRC
We next elucidated whether miR-148a status had a potential for
predicting therapeutic outcome in patients with stage IV CRC
treated with 5-FU and oxaliplatin. Age, gender, tumor location,
and performance status were not significantly different between
the high and low expression groups (Table 1). Tumors from non-
responders (stable disease and progressive disease) showed a trend
toward lower miR-148a expression compared with those from
responders (complete response and partial response) (median,
0.063 vs. 0.092, p = 0.10; Figure 3A, left). Nonetheless, when the
stage IV tumors were divided into the low and high miR-148a
expression groups, the low expression group was significantly
associated with an unfavorable therapeutic response (responders,
49% vs. 81%, p = 0.006; Figure 3A, right). At Kaplan-Meyer
analysis, the low expression group showed a trend toward worse
PFS (median, 8.1 vs. 10.1 months, p = 0.16; Figure 3B, left) and
significantly worse OS (16.1 vs. 25.6 months, p = 0.024;
Figure 3B, right). In addition to the expression status, miR-
148a methylation status also associated with both worse PFS
(methylated vs. non-methylated, 6.9 vs. 9.3 months, p = 0.020;
Figure 3C, left) and OS (10.2 vs. 21.8 months, p = 0.0015;
Figure 3C, right).
We also evaluated the predictive value of miR-148a in a Cox
proportional-hazard model. In univariate analysis, worse PS (HR
Table 2. Univariate and multivariate analysis of miR-148a expression and DFS in stage II/III CRC patients.
II+III III only
Univariate Multivariate Univariate
Variables n HR (95%CI) p HR (95%CI) p n HR (95%CI) p
Age, years .60 143 1.0 1.0 33 1.0
,60 58 1.57 (0.97–2.56) 0.071 1.78 (1.09–2.92) 0.022b 92 1.42 (0.79–2.56) 0.24
Gender Male 118 1.0 78 1.0
Female 83 0.97 (0.60–1.57) 0.91 47 0.89 (0.50–1.60) 0.71
Tumor locationa Proximal 61 1.0 49 1.0
Distal 140 0.92 (0.55–1.51) 0.73 76 1.15 (0.64–2.07) 0.64
MSI No 187 1.0 117 1.0
Yes 14 0.78 (0.29–2.13) 0.63 8 1.35 (0.49–3.73) 0.57
Stage II 76 1.0 1.0
III 125 2.06 (1.21–3.52) 0.008b 2.06 (1.20–3.53) 0.009b
miR-148a expression High 138 1.0 1.0 80 1.0
Low 63 1.74 (1.08–2.83) 0.025b 1.83 (1.12–2.99) 0.017b 45 2.11 (1.21–3.68) 0.009b
aProximal colon, located above splenic flexture; distal colon, located in splenic flexture or below.
bp,0.05.
doi:10.1371/journal.pone.0046684.t002
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2.62, 95% CI 1.26–5.43, p = 0.010), lower miR-148a expression
(HR 1.79, 95% CI 1.08–2.98, p = 0.026) and miR-148a
hypermethylation (HR 2.76, 95% CI 1.44–5.28, p = 0.002) were
significantly associated with worse survival (Table 3). In the final
multivariate model that included these three factors, both miR-
148a expression status (HR 1.93, 95% CI 1.15–3.23, p = 0.014)
and miR-148a hypermethylation (HR 3.04, 95% CI 1.56–5.93,
p = 0.0011) emerged as independent predictive factors that were
associated with poorer outcome (Table 3).
Discussion
The aim of this study was to elucidate whether miR-148a
expression is dysregulated in CRC, and furthermore, if this has the
potential to serve as a prognostic or predictive biomarker in this
disease. Herein, we provide evidence that highlight a significant
role for miR-148a dysregulation in CRC. First, miR-148a
expression was frequently down-regulated in CRC, particularly
in advanced stage tumors. Second, miR-148a expression in colon
was regulated at least in part through epigenetic mechanisms
based upon the inverse correlation observed between its expression
and methylation status. Third, low miR-148a expression was
independently associated with poor prognosis in stage III patients
treated with adjuvant chemotherapy. Fourth, low miR-148a
expression was also associated with worse therapeutic response
and poorer survival in stage IV patients treated with chemother-
Figure 3. Associations between miR-148a status and therapeutic response or survival in stage IV CRC patients treated with 5-FU
and oxaliplatin. A. Therapeutic response according to miR-148a expression. Complete response, CR; partial response, PR; stable disease, SD;
progressive disease; PD. B. Kaplan-Meyer curves for progression-free survival (PFS, left panel) and OS (right panel) in stage IV patients according to
miR-148a expression. C. Kaplan-Meyer curves for PFS (left panel) and OS (right panel) in stage IV patients according to miR-148a methylation.
doi:10.1371/journal.pone.0046684.g003
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apy. Finally, the methylation status was an independent predictor
for worse prognosis in stage IV CRC.
In vitro studies using non-colonic cell lines have indicated that
miR-148a exerts a tumor suppressive function by targeting several
genes such as PXR, TGIF2, MSX1, CDC25B, DNMT1 and
DNMT3b [39,42–46]. The dysregulation of miR-148a has been
implicated in CRC [14,29,39,47], however, the clinical signifi-
cance of altered miR-148a expression in CRC remains to be fully
elucidated. In our study, we have analyzed the largest cohort of
CRC patients to date (n = 273) and provided robust evidence that
miR-148a expression is frequently down-regulated in advanced
CRC and its reduced expression is associated with worse survival
in stage III and IV disease. To the best of our knowledge, none of
the previous reports have embarked upon the identification of
miRNAs as biomarkers for predicting the therapeutic response in
stage IV CRC patients treated with cytotoxic chemotherapy. Our
most clinically important observation was that stage IV CRC
patients with high miR-148a expression were more likely to benefit
from cytotoxic chemotherapy, highlighting the potentially novel
predictive value of this miRNA as a decision-making tool in the
management of patients with CRC.
The precise mechanisms underlying miR-148a down-regulation
in promoting resistance of CRC cells to chemotherapy require
further elucidation. However, recent evidence for the role of this
miRNA in other cancers have offered clues for understanding
some of its effects on cellular chemosensitivity. Fujita et al. reported
that miR-148a directly targets MSK1 and the transfection of its
precursor enhanced sensitivity to paclitaxel in prostate cancer cells
[43]. miR-148a expression has also been shown to improve
response to cisplatin and 5-FU in esophageal cancer cells [48]. In
addition to these in vitro findings, in young patients with acute
myeloid leukemia, higher BAALC gene expression correlates
inversely with miR-148a expression, and has been shown to
associate with worse outcome in patients treated with chemother-
apy [49]. Collectively, our observations for the potential of miR-
148a expression status as a predictive marker in stage IV CRC
concur with these previous publications in other cancers.
Our study is also the first attempt to confirm methylation-
mediated silencing of miR-148a by directly comparing expression
and methylation levels in a large cohort of well-annotated CRCs.
In addition to the initial studies by Lujambio et al. [39], more
recently it was shown that miR-148a was hypermethylated in 51
out of 78 CRCs [40]. However, neither of these studies performed
miR-148a expression analysis and directly correlated their results
with hypermethylation in tissues. Furthermore, both studies
analyzed miR-148a methylation status using a non-quantitative
methylation-specific PCR method, which is notoriously non-
specific for methylation, and does not provide a threshold for
methylation that correlates with transcriptional inactivation of the
gene. The strength of our study is that we determined miR-148a
expression by qRT-PCR, and correlated the expression data with
quantitative bisulfite pyrosequencing results, which is a more
robust approach for demonstrating methylation-mediated dysreg-
ulation of any gene. Accordingly, we observed a significant inverse
association between methylation and expression, reinforcing the
concept that miR-148a down-regulation in CRC is due, in part, to
promoter hypermethylation. We also noted a significant and
independent association between miR-148a methylation and poor
survival in stage IV patients, highlighting that expression and
methylation status of miR-148a might be useful as prognostic/
predictive markers in CRC. Finally, we confirmed our RT-PCR-
based expression results by performing ISH on FFPE tissues,
which allows a direct morphologic representation of the miRNA
expression in the tissues. In these experiments we observed a
significant correlation between qRT-PCR and ISH data, which
suggests a potential translational application of ISH in clinical
practice.
It should be noted that, our results in stage IV CRC implicates
the predictive value of miR-148a expression status, however, it is
still unclear that the miR-148a expression status has a prognostic,
or predictive value, or both, in stage II and III CRC. In our study,
all patients with stage II and III CRC were treated with 5-FU-
based adjuvant chemotherapy, therefore, further cohorts of
patients including both treated and non-treated with adjuvant
chemotherapy are required to determine the prognostic and/or
predictive value of the miR-148a expression status in stage II and
III CRC.
Table 3. Univariate and multivariate analysis of miR-148a expression, methylation and overall survival in stage IV MSS CRC
patients.
Univariate Multivariate
n HR (95%CI) p HR (95%CI) p
Age (years) .60 35 1.0
,60 36 0.91 (0.55–1.50) 0.71
Gender Male 46 1.0
Female 25 0.68 (0.40–1.16) 0.16
Tumor location Colon 58 1.0
Rectum 13 1.41 (0.76–2.60) 0.27
Performance status 0–1 1.0
2 2.62 (1.26–5.43) 0.010a
miR-148a expression High 36 1.0 1.0
Low 35 1.79 (1.08–2.98) 0.026a 1.93 (1.15–3.23) 0.014a
miR-148a methylation No 59 1.0 1.0
Yes 12 2.76 (1.44–5.28) 0.002a 3.04 (1.56–5.93) 0.0011a
ap,0.05.
doi:10.1371/journal.pone.0046684.t003
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In conclusion, our study describes the clinical significance of
miR-148a in CRC, wherein we demonstrate that its expression is
frequently down-regulated, particularly in advanced stage tumors.
Furthermore, this study builds upon growing evidence that
miRNA expression can be epigenetically regulated. Our data
indicate that miR-148a expression, as well as its methylation
status, may serve as predictive biomarkers in CRC. Our data
provide a rationale for undertaking future studies to further
validate the predictive value of miR-148a in the management of
CRC patients treated with conventional chemotherapy and/or
combinations of molecular-targeted drugs.
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